



Clinical Policy: Tadalafil (Adcirca, Alyq, Tadliq)

Reference Number: MDN.CP.PHAR.198

Effective Date: 04.01.22

Last Review Date: 9.21.22

Line of Business: Meridian IL Medicaid

Coding Implications

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

Description

Tadalafil (Adcirca[®], Alyq[™], Tadliq[®]) is a phosphodiesterase-5 inhibitor.

FDA Approved Indication(s)

Adcirca, Alyq, and Tadliq are indicated for the treatment of pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group 1) to improve exercise ability.

Studies establishing effectiveness included predominately patients with New York Heart Association (NYHA) Functional Class II-III symptoms and etiologies of idiopathic or heritable PAH (61%) or PAH associated with connective tissue diseases (23%).

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation[®] that tadalafil is **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

A. Pulmonary Arterial Hypertension (must meet all):

1. Diagnosis of PAH;
2. Prescribed by or in consultation with a cardiologist or pulmonologist;
3. Failure of a calcium channel blocker (*see Appendix B*), unless member meets one of the following (a or b):
 - a. Inadequate response or contraindication to acute vasodilator testing;
 - b. Contraindication or clinically significant adverse effects to calcium channel blockers are experienced;
4. If request is for brand Adcirca, Alyq, or Tadliq member must use generic tadalafil, unless contraindicated or clinically significant adverse effects are experienced;
5. Dose does not exceed one of the following (a or b):
 - a. Adcirca or Alyq: 40 mg (2 tablets) per day.
 - b. Tadliq: 2 bottles (300mL) per month

Approval duration: 6 months

B. Other diagnoses/indications (must meet 1 or 2)

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):

Clinical Policy:

Tadalafil (Adcirca, Alyq, Tadli)

- a. For drugs on the PDL: CP.PMN.255; or
 - b. For drugs NOT on the PDL: CP.PMN.16; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy: CP.PMN.53.

Clinical Policy:

Tadalafil (Adcirca, Alyq, Tadli)

II. Continued Therapy

A. Pulmonary Arterial Hypertension (must meet all):

1. Member meets one of the following (a or b):
 - a. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
 - b. Member is currently receiving medication and is enrolled in a state and product with continuity of care regulations (*refer to state specific addendums for CC.PHARM.03A and CC.PHARM.03B*) Currently receiving medication via Centene benefit or member has previously met
2. Member is responding positively to therapy;
3. If request is for brand Adcirca, Alyq or Tadliq, member must use generic tadalafil, unless contraindicated, clinically significant adverse effects are experienced, or for Tadliq requests member is unable to swallow tablets;
4. If request is for a dose increase, new dose does not exceed one of the following (a or b):
 - a. Adcirca, Alyq: 40 mg (2 tablets) per day;
 - b. Tadliq: 2 bottles (300 mL) per month.
5. If request is for a dose increase, new dose does not exceed 40 mg (2 tablets) per day.

Approval duration: 12 months

B. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
 - a. For drugs on the PDL: CP.PMN.255; or
 - b. For drugs NOT on PDL, the non-formulary policy refer to CP.PMN.16 or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy CP.PMN.53.

III. Diagnoses/Indications for which coverage is NOT authorized:

- ### A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.PMN.53 for Medicaid, or evidence of coverage documents.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

FC: functional class

FDA: Food and Drug Administration

NYHA: New York Heart Association

PAH: pulmonary arterial hypertension

PH: pulmonary hypertension

WHO: World Health Organization

Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent and may require prior authorization.

Clinical Policy:

Tadalafil (Adcirca, Alyq, Tadli)

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
nifedipine (Adalat [®] CC, Afeditab [®] CR, Procardia [®] , Procardia XL [®])	60 mg PO QD; may increase to 120 to 240 mg/day	240 mg/day
diltiazem (Dilacor XR [®] , Dilt-XR [®] , Cardizem [®] CD, Cartia XT [®] , Tiazac [®] , Taztia XT [®] , Cardizem [®] LA, Matzim [®] LA)	720 to 960 mg PO QD	960 mg/day
amlodipine (Norvasc [®])	20 to 30 mg PO QD	30 mg/day

Therapeutic alternatives are listed as Brand name[®] (generic) when the drug is available by brand name only and generic (Brand name[®]) when the drug is available by both brand and generic.

Appendix C: Contraindications/Boxed Warnings

- Contraindication(s)

Clinical Policy:

Tadalafil (Adcirca, Alyq, Tadli)

- Concomitant organic nitrates
 - Concomitant guanylate cyclase stimulators
 - Hypersensitivity reactions
- Boxed warning(s): none reported

Appendix D: Pulmonary Hypertension: WHO Classification

- Group 1: PAH (pulmonary arterial hypertension)
- Group 2: PH due to left heart disease
- Group 3: PH due to lung disease and/or hypoxemia
- Group 4: CTEPH (chronic thromboembolic pulmonary hypertension)
- Group 5: PH due to unclear multifactorial mechanisms

Appendix E: Pulmonary Hypertension: WHO/NYHA Functional Classes (FC)

Treatment Approach*	FC	Status at Rest	Tolerance of Physical Activity (PA)	PA Limitations	Heart Failure
Monitoring for progression of PH and treatment of co-existing conditions	I	Comfortable at rest	No limitation	Ordinary PA does not cause undue dyspnea or fatigue, chest pain, or near syncope.	
Advanced treatment of PH with PH-targeted therapy - see Appendix F**	II	Comfortable at rest	Slight limitation	Ordinary PA causes undue dyspnea or fatigue, chest pain, or near syncope.	
	III	Comfortable at rest	Marked limitation	Less than ordinary PA causes undue dyspnea or fatigue, chest pain, or near syncope.	
	IV	Dyspnea or fatigue may be present at rest	Inability to carry out any PA without symptoms	Discomfort is increased by any PA.	Signs of right heart failure

*PH supportive measures may include diuretics, oxygen therapy, anticoagulation, digoxin, exercise, pneumococcal vaccination. **Advanced treatment options also include calcium channel blockers.

Appendix F: Pulmonary Hypertension: Targeted Therapies

Mechanism of Action	Drug Class	Drug Subclass	Drug	Brand/Generic Formulations
Reduction of pulmonary arterial pressure	Prostacyclin* pathway agonist	Prostacyclin	Epoprostenol	Veletri (IV) Flolan (IV) Flolan generic (IV)
	*Member of the prostanoid class	Synthetic prostacyclin analog	Treprostinil	Orenitram (oral tablet)

Clinical Policy:

Tadalafil (Adcirca, Alyq, Tadli)

Mechanism of Action	Drug Class	Drug Subclass	Drug	Brand/Generic Formulations
through vasodilation	<i>of fatty acid derivatives.</i>			Remodulin (IV) Tyvaso (inhalation)
			Iloprost	Ventavis (inhalation)
		Non-prostanoid prostacyclin receptor (IP receptor) agonist	Selexipag	Uptravi (oral tablet)
	Endothelin receptor antagonist (ETRA)	Selective receptor antagonist	Ambrisentan	Letairis (oral tablet)
		Nonselective dual action receptor antagonist	Bosentan	Tracleer (oral tablet)
			Macitentan	Opsumit (oral tablet)
	Nitric oxide-cyclic guanosine monophosphate enhancer	Phosphodiesterase type 5 (PDE5) inhibitor	Sildenafil	Revatio (IV, oral tablet, oral suspension)
			Tadalafil	Adcirca (oral tablet)
		Guanylate cyclase stimulant (sGC)	Riociguat	Adempas (oral tablet)

V. Dosage and Administration

Drug Name	Dosing Regimen	Maximum Dose
Adcirca, Alyq	40 mg PO QD	40 mg/day
Tadliq	40mg (10mL) PO QD	40mg/day

VI. Product Availability

Drug Name	Availability
Adcirca, Alyq	Tablet: 20 mg
Tadliq	Oral suspension: 20 mg/5 mL in 150 mL bottle

VII. References

1. Adcirca Prescribing Information. Indianapolis, IN: Eli Lilly and Company; September 2020. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022332Orig1s0111bl.pdf. Accessed November 9, 2021.
3. Alyq Prescribing Information. North Wales, PA: Teva Pharmaceuticals Inc.; September 2021. Available at: <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3a404db2-7a7d-476f-81cf-979a67d37f66>. Accessed November 9, 2021. Tadliq Prescribing Information. Farmville, NC: CMP Pharma, Inc.; June 2022. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214522s0001bl.pdf. Accessed August 22, 2022.

Clinical Policy:

Tadalafil (Adcirca, Alyq, Tadli)

4. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: A report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association - developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. *J Am Coll Cardiol*. 2009; 53(17): 1573-1619.
5. Klinger JR, Elliott CG, Levine DJ, et al. Therapy for pulmonary arterial hypertension in adults: update of the CHEST guideline and expert panel report. *CHEST*. 2019;155(3):565-586. doi: <https://doi.org/10.1016/j.chest.2018.11.030>.
6. Abman SH, Hansmann G, Archer SL, et al. Pediatric pulmonary hypertension: Guidelines from the American Heart Association and American Thoracic Society. *Circulation*. 2015; 132(21): 2037-99.
7. Kim NH, Delcroix M, Jenkins DP, et al. Chronic thromboembolic pulmonary hypertension. *J Am Coll Cardiol*. 2013; 62(25): Suppl D92-99.
8. Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of Pulmonary Hypertension. *European Heart Journal*. Doi:10.1093/eurheartj/ehv317.
9. Simonneau G, Montani D, Celermajer D, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. *Eur Respir J*. 2019; 53:1801913.
10. Sitbon O, Humbert M, Jais X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. *Circulation*. 2005;111(23):3105-11.
11. Yaghi S, Novikov A, Trandafirescu T. Clinical update on pulmonary hypertension. *J Investig Med*. 2020; 0:1-7. doi:10.1136/jim-2020-001291.

Reviews, Revisions, and Approvals	Date	P&T Approval Date
Policy created, adapted from CP.PHAR.198	04.01.22	04.22
RT4: newly approved oral suspension formulation Tadliq added to policy. Template changes applied to other diagnoses/indications and continued therapy section.	9.21.22	

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

Clinical Policy:

Tadalafil (Adcirca, Alyq, Tadli)

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note:

For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2016 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.

Clinical Policy:

Tadalafil (Adcirca, Alyq, Tadli)